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The central amygdala (CeA) is a key structure at the
limbic-motor interface regulating stress responses
and emotional learning. Endocannabinoid (eCB)
signaling is heavily implicated in the regulation of
stress-response physiology and emotional learning
processes; however, the role of eCBs in the modula-
tion of synaptic efficacy in the CeA is not well under-
stood. Here we describe the subcellular localization
of CB1 cannabinoid receptors and eCB synthetic
machinery at glutamatergic synapses in the CeA
and find that CeA neurons exhibit multiple mechanis-
tically and temporally distinct modes of postsynaptic
eCB mobilization. These data identify a prominent
role for eCBs in the modulation of excitatory drive
to CeA neurons and provide insight into the mecha-
nisms by which eCB signaling and exogenous
cannabinoids could regulate stress responses and
emotional learning.
INTRODUCTION
The central amygdala (CeA) plays a key role in emotional learning
processes (Ehrlich et al., 2009; Pape and Pare, 2010). Perhaps
most well-studied is the role the CeA plays in unconditioned
and conditioned fear generation (Ciocchi et al., 2010; Li et al.,
2013; Tye et al., 2011), fear extinction, and conditioned inhibition
(Amano et al., 2010), as well as conditioned orienting responses
to emotionally salient stimuli (El-Amamy and Holland, 2007;
Groshek et al., 2005). The CeA is a subcortical structure
composed of GABAergic neurons and divided into lateral
(CeAL) and medial (CeAM) subdivisions (Cassell et al., 1999).
The CeAL acts as the primary input nucleus of the CeA and
receives strong glutamatergic drive from cortical (McDonald
et al., 1999), thalamic (Li and Kirouac, 2008), intra-amygdala,
and brainstem sources (Dong et al., 2010) and projectsGABAergic axon terminals to the CeAM (Sun et al., 1994). The
CeAM, in turn, projects to downstream regions involved in the
expression of fear and arousal responses to salient stimuli
(Davis, 1997). Functional studies have recently shown that acti-
vation of CeAL projection neurons strongly inhibits CeAM output
neurons and reduces behavioral fear and anxiety responses
(Ciocchi et al., 2010; Li et al., 2013; Tye et al., 2011). Thus,
enhanced inhibitory control of CeAM neurons by elevated activ-
ity of CeAL projection cells may serve to constrain conditioned
fear and anxiety (Amano et al., 2010; Ciocchi et al., 2010). Taken
together, these data suggest that understanding the synaptic
mechanisms regulating excitatory drive to CeAL neurons could
provide significant insight into the mechanisms regulating the
expression of fear and anxiety.
Endocannabinoids are a class of bioactive lipids produced by
neurons and glia (Kano et al., 2009). 2-arachidonoylglycerol
(2-AG) is thought to be the primary eCB that mediates retro-
grade synaptic signaling at central synapses (Castillo et al.,
2012). 2-AG is postsynaptically synthesized by diacylglycerol
lipase a (DAGLa) via calcium- and Gq-protein-coupled receptor
(GqPCR)-dependent mechanisms (Hashimotodani et al., 2005,
2007; Ohno-Shosaku et al., 2005, 2012). In contrast to 2-AG,
the mechanisms regulating synaptic anandamide (AEA) synthe-
sis are not well understood but can involve GqPCR activation
(Cha´vez et al., 2010; Grueter et al., 2010; Huang and Woolley,
2012). Once produced, 2-AG and AEA are primarily degraded
by monoacylglycerol lipase and fatty acid amide hydrolase,
respectively (Cravatt et al., 2001; Dinh et al., 2002; Long et al.,
2009).
Despite the prominent role of eCB signaling in the regula-
tion of fear, anxiety, and stress responses (Hill et al., 2010;
Lutz, 2007; Ramikie and Patel, 2012; Riebe et al., 2012),
the role of eCB signaling in the modulation of CeA circuitry
has been relatively under-investigated due to anatomical
studies that demonstrated very weak CB1 receptor immunore-
activity within the CeA (Kamprath et al., 2011; Katona et al.,
2001). Here, we utilized new reagents to reveal abundant
expression of eCB signaling elements at CeAL glutamatergic
synapses and elucidate several mechanistically and temporallyNeuron 81, 1111–1125, March 5, 2014 ª2014 Elsevier Inc. 1111
Figure 1. CB1 Receptors Are Present on
Excitatory Terminals in the CeAL
(A) In situ hybridization reveals the presence of
CB1 mRNA in both the CeA and the BLA of wild-
type mice.
(B) The specificity of the riboprobe is confirmed by
using CB1 KO animals.
(C) The very high levels of CB1 mRNA observed
in a few scattered neurons in the BLA likely
correspond to GABAergic interneurons. The vast
majority of BLA neurons express moderate levels
of CB1 mRNA. In contrast, CB1 mRNA expression
in the CeA was only slightly above detection
threshold.
(D and E) Immunoperoxidase staining demon-
strates the presence of the CB1 protein in both the
CeA and BLA, which was confirmed in our CB1 KO
samples.
(F) Higher magnification light micrographs reveal
the dense CB1 labeling in the neuropil throughout
the CeAL. Asterisks depict CB1-immunonegative
cell bodies, whereasCB1-immunopositive labeling
appears as punctate staining indicating the com-
partmentalized distribution of the protein.
(G1 and G2) Serial electron micrographs illustrate
the selective presynaptic accumulation of CB1 in
boutons (b+), which form mainly asymmetric
(flanked by black arrowheads; see inset [I]) and
sometimes symmetric (white arrowheads; see
inset [H]) synapses with dendrites (d) and spine
heads (s). CB1 staining remained under detection
threshold in a few axon terminals (b-), which
highlights quantitative differences in CB1 expres-
sion between terminal types innervating the CeAL.
(H and I) The anatomical nature of the synapse
type is illustrated at higher magnification. Scale
bars are as follows: (A), (B), (D), and (E) are 200 mm;
(C) is 50 mm; (F) is 20 mm; and (G1), (G2), (H), and (I)
are 100 nm.
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rons subserving synaptic depression of CeAL glutamatergic
neurotransmission.
RESULTS
Localization of Endocannabinoid SignalingMachinery in
the CeAL
Although prior studies suggested a negligible role for eCBs in
the modulation of CeA synaptic signaling (Katona et al., 2001),
our in situ hybridization studies revealed a detectable CB1
in situ signal within the CeA and strong expression in the baso-
lateral amygdala (BLA) of wild-type (WT), but not CB1 knockout
(KO; Crn1/), mice (Figures 1A–1C). The presence of CB1
mRNA in the majority of BLA neurons, which project gluta-
matergic afferents to the CeAL, suggested that BLA-CeA
glutamatergic terminals might express CB1 receptor protein
(Figure 1C). Therefore, we employed a new high-affinity anti-
CB1 antibody to probe the localization of CB1 receptors in the
CeA (Yoshida et al., 2011). Using this antibody, CB1 receptors
were clearly detected at high levels in both the CeAL and
CeAM of WT, but not Crn1/ mice (Figures 1D–1F). Addition-
ally, electron microscopic (EM) examination revealed CB1 re-1112 Neuron 81, 1111–1125, March 5, 2014 ª2014 Elsevier Inc.ceptor expression in presynaptic boutons forming asymmetric
synapses onto dendritic shafts and spines within the CeAL (Fig-
ures 1G1, 1G2, and 1I).
Considering that 2-AG is the primary ligand mediating eCB
retrograde signaling at central synapses, we next examined
the expression of the 2-AG synthesizing enzyme, DAGLa, in
theCeA. In situ hybridization confirmed the expression of DAGLa
in both the BLA and CeA (Figures 2A–2C). Immunohistochem-
istry, using an anti-DAGLa antibody whose specificity in the fore-
brain has been confirmed inDagla/mice (Luda´nyi et al., 2011),
uncovered a punctate staining pattern throughout the CeAL (Fig-
ures 2D and 2E). Double immunofluorescence labeling and
confocal microscopy revealed DAGLa-positive puncta in close
apposition toMAP2-labeled dendritic shafts in the CeAL (Figures
2F–2H), suggestive of DAGLa localization in presynaptic or post-
synaptic compartments. To differentiate between these two
possibilities, we performed immunoperoxidase labeling and uti-
lized EM to visualize DAGLa at the synaptic level. We found that
DAGLa was indeed localized postsynaptically in dendritic shafts
and spine heads forming asymmetric synapses in the CeAL (Fig-
ures 2I–2L). Taken together, these data demonstrate the pres-
ence of eCB signaling elements at glutamatergic synapses in
the CeAL.
Figure 2. DAGLa Is a Postsynaptic Enzyme
in the CeAL
(A and B) In situ hybridization demonstrates the
expression of DAGLa mRNA in both the BLA and
CeA. AS and S depict experiments performed by
antisense and sense riboprobes, respectively.
(C) Expression of DAGLa mRNA is notably higher
in the BLA compared to the CeA.
(D) However, at the protein level there is less dif-
ference between the two regions.
(E) High magnification of the boxed region in (D)
reveals that granular DAGLa-immunoreactivity
(labeled by arrows) is present in the neuropil
among cell bodies.
(F–H) Confocal immunofluorescence analysis
shows that DAGLa immunoreactivity (red puncta
indicated by white arrows) outlines MAP2-positive
dendritic profiles (green). Asterisks denote CeAL
cell bodies.
(I–L) Electron micrographs provide ample evi-
dence for the postsynaptic localization of DAGLa.
Immunoreactivity represented by the black dia-
minobenzidine (DAB) precipitate was often pre-
sent in dendrites (d+) and spine heads (s+), but
never in boutons (b). Black arrowheads highlight
asymmetric synapses. Scale bars are as follows:
(A) and (B) are 200 mm; (C) and (D) are 50 mm; (E) is
20 mm; (F) is 5 mm; (G) and (H) are 2.5 mm; and (I)–(L)
are 100 nm.
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To determine the functional significance of CB1 receptor expres-
sion in the CeAL, we conducted whole-cell voltage-clamp
electrophysiological recordings in the presence of picrotoxin
(25–50 mM) to isolate glutamatergic currents. Consistent with
the localization of CB1 receptors on excitatory axon terminals
in the CeAL, we found that activation of CB1 receptors with the
cannabinoid agonist CP55940 (5 mM) significantly depressed
evoked excitatory postsynaptic current (eEPSC) amplitude to
52%± 4%of baseline in CeAL neurons fromWTmice—an effect
absent in cells from Crn1/ mice (WT 52.47% ± 3.94% vs.
Crn1/ 114% ± 8%; t(8)=7.18, p<0.0001) (Figures 3A and 3B).
No significant effect on paired pulse ratio (PPR) was observed
following 5 mM CP55940 application to WT or Crn1/ cells
(normalized PPR, WT 1.06 ± 0.06 vs. Crn1/ 0.89 ± 0.06; t(8)
=2 and p=0.08) (Figure 3C). However, analysis of spontaneous
EPSCs (sEPSCs) revealed a selective effect of 5 mM CP55940
to reduce sEPSC frequency (vehicle 4.35 ± 0.92 Hz vs.Neuron 81, 1111–112CP55940 1.59 ± 0.27 Hz; U=50.00 and
p=0.008), but not amplitude (vehicle
20.99 ± 1.00 pA vs. CP55940 22.80 ±
2.20 pA; U=9, p=0.32; Figure 3D–3F), by
Mann-Whitney U test.
Although the selective effect of
CP55940 on frequency, but not ampli-
tude, of sEPSCs suggests a presynaptic
locus of action, the lack of effect on
PPR was surprising. Therefore, we evalu-ated the effects of 2-AG-ether, a metabolically stable analog of
2-AG, to better elucidate the mechanisms by which eCB
signaling (Hanus et al., 2001), rather than a synthetic CB1
agonist, modulates glutamate release. Indeed, 50 mM 2-AG-
ether caused robust synaptic depression (baseline 100.3% ±
1.2% vs. 2-AG-ether 49.1% ± 9.5%; t(3)=6.13, p<0.01 by paired
t test) (Figure 3G) that was associated with a significant increase
in PPR (t(3)=3.9, p<0.05 by paired t test) (Figure 3G, inset). These
data indicate that CB1 receptors function to suppress glutamate
release onto CeAL neurons.
Since CB1 receptors in other brain regions robustly modulate
GABAergic transmission (Castillo et al., 2012; Kano et al.,
2009), we also tested the effects of CP55940 (5 mM) on
GABAergic currents in the CeAL recorded in the presence of
CNQX (20 mM) and AP-5 (50 mM). Generally consistent with our
previous report (Katona et al., 2001), and our EM observation
of only a fewCeALGABAergic terminals being CB1-positive (Fig-
ures 1G1, 1G2, and 1H), the effect on GABAergic currents
was smaller and highly variable (baseline 100.0% ± 0.0% vs.5, March 5, 2014 ª2014 Elsevier Inc. 1113
Figure 3. CB1 Receptors Modulate Glutamate Release in the CeAL
(A–C) CP55940 depresses eEPSC amplitude in WT but not CB1
/ mice, but it does not affect PPR.
(D–F) CP55940 reduces sEPSC frequency (E) but not amplitude (F).
(G) 2-AG-ether depresses eEPSC amplitude and increases PPR (inset).
(legend continued on next page)
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Endocannabinoid Signaling in the Central Amygdala76.1% ± 9.3%; t(7)=2.6, p<0.05) (Figure 3H). When compared to
the effect of CP55940 (5 mM) on glutamatergic transmission
(from CeAL cells depicted in Figure 3B), CP55940-induced
depression of GABAergic currents showed a significantly greater
variance compared to its effects on glutamate release (F test to
compare variances, p<0.05) (Figure 3I). These data suggest that
the major role of CB1 signaling in the CeAL is to broadly regulate
glutamatergic transmission, while synapse- or cell-type-specific
modulation of GABAergic transmission may also occur.
Ca2+-Driven eCB Release in the CeAL
We next examined whether CeAL glutamatergic synapses ex-
press depolarization-induced suppression of excitation (DSE),
a Ca2+-DAGLa-dependent form of 2-AG-mediated eCB retro-
grade signaling (Ohno-Shosaku et al., 2012). Two-way ANOVA
revealed a significant effect of DSE induction (depolarization)
and postsynaptic depolarization duration (Figures 3J–3L). Post
hoc Sidak’s analysis revealed depolarization of CeAL neurons
from 70 to 0 mV resulted in a transient depression of eEPSC
amplitude that was significantly different from corresponding
baseline values after 5 s (p<0.0001) and 10 s (p<0.0001) of
postsynaptic depolarization. One-way ANOVA followed by
Dunnett’s post hoc analysis revealed that CeAL 10 s DSE was
blocked by the CB1 receptor antagonist SR141716 (control
77.65% ± 2.06% vs. 5 mM SR141716 95.84% ± 4.84%,
p<0.001) (Figures 3M–3O) and absent in Crn1/ mice (Crn1/
102.5% ± 3.84%, p<0.0001) (Figure 3O). DSE was also blocked
by the DAGL inhibitor THL (10 mMTHL 91.20% ± 2.13%, p<0.05)
(Figure 3O) and postsynaptic calcium chelation with 40 mM
BAPTA (BAPTA 92.07% ± 1.46%, p<0.05) (Figure 3O), indicating
that Ca2+-driven short-term eCB mobilization at CeAL gluta-
matergic synapses is mediated by 2-AG activation of CB1 recep-
tors. Intracellular loading of BAPTA alone did not affect fre-
quency or amplitude of sEPSCs in CeAL neurons (control
frequency 4.35 ± 0.9 Hz vs. BAPTA 4.1 ± 1.0 Hz, p>0.05; control
amplitude 21.0 ± 1.0 pA vs. BAPTA 25.1 ± 2.6, p>0.05) (Figure S1
available online).
Ca2+-Assisted mAChR-Driven eCB Release in the CeAL
In addition to Ca2+-dependent eCB release, Gq-receptor-driven
eCB mobilization is a common feature of central synapses
(Katona and Freund, 2012). For example, in the hippocampus,
activation of Gq-coupledM1/M3muscarinic acetylcholine recep-
tors (mAChRs) has been shown to mobilize eCB signaling in a
calcium-independent manner (Kim et al., 2002; Straiker and
Mackie, 2007). Importantly, mAChRs are also highly expressed
in the CeAL (Roozendaal et al., 1997; van der Zee et al., 1997).
To determine whether activation of mAChRs drives eCB mobili-(H) CP55940 decreases eIPSC amplitude.
(I) Comparison of CP55940 effects on eIPSC and eEPSC amplitudes.
(J–L) Effects of postsynaptic depolarization on eEPSC amplitude; DSE in represen
depolarization relative to corresponding baseline (L).
(M and N) Effects of SR141716 on DSE after 10 s depolarization.
(O) Summary data showing effects of SR141716, CB1 deletion, THL, and intrace
group in (O) represents the same data set as 10 s depolarization in (L). *p<0.05, **
bars for this and subsequent figures. Calibration scale bars in (A) are 200 pA, 25 m
and higher magnification (10 pA, 20 ms). All other scale bars are as follows: 10 mzation in the CeAL, we first sought to examine the functional
effects of mAChR activation on CeAL glutamatergic transmis-
sion. Experimental results from CeAL field potential recordings
demonstrated that bath application of the mAChR agonist,
Oxo-M (1 mM), reduced the amplitude of field excitatory postsyn-
aptic potentials (fEPSPs) to 44.40% ± 3.69% of baseline (base-
line 100.90% ± 1.18% vs. maximal Oxo-M-induced depression
44.40%± 3.69%, p<0.0001 by paired t test) (Figure 4A), an effect
that reversed following drug washout (baseline 100.90% ±
1.18% vs. post-Oxo-M washout 96.14% ± 7.13%, p=0.79 by
paired t test) (Figure 4A). To test whether this Oxo-M-induced
depression wasmediated bymAChR activation, we bath applied
1 mM atropine, a nonselective mAChR antagonist, prior to
and during Oxo-M (1 mM) application. Atropine application
completely blocked the effect of 1 mM Oxo-M on fEPSPs (base-
line 100.3% ± 0.79% vs. atropine+Oxo-M 96.47% ± 4.38%,
p=0.87 by paired t test) (Figure 4A). Using whole-cell recordings,
we found that Oxo-M caused robust depression of eEPSC
amplitude, an effect reduced by theM1-preferring antagonist pir-
enzepine (1 mM; p<0.0001) and eliminated by the M3-preferring
antagonist 4-DAMP (500 nM, p<0.0001) (Figure 4B). Oxo-M-
induced synaptic depression was associated with a large in-
crease in PPR, which was attenuated by pirenzepine (p<0.001)
and blocked by 4-DAMP (p<0.0001) (Figure 4C), suggesting
Oxo-M-induced synaptic depression is mediated by M1/3 recep-
tor activation and expressed presynaptically. Importantly,
neither pirenzepine nor 4-DAMP exerted any effects on glutama-
tergic transmission when applied alone to control CeAL slices
(Figure S2). Additionally, our immunofluorescence confocal
microscopy data revealed a moderate expression of the M1 re-
ceptor subtype throughout the CeAL (Figures 4E1 and 4E2). At
high magnification, M1 staining appears as tiny puncta closely
apposed to, but not overlapping with, MAP2-positve dendrites
and perikarya. Together, these data demonstrate the presence
of functional M1/3 mAChRs in the CeAL.
Given the functional presence of M1/3 mAChRs at CeAL
glutamatergic synapses, we next evaluated the presence of
mAChR-driven eCB release at excitatory synapses within the
CeAL. It has been previously reported that DSE is effectively
enhanced by the coincidental activation of Gq-coupled recep-
tors, such as M1/M3 receptors, via a mechanism involving Ca
2+
enhancement of PLCb activity (Hashimotodani et al., 2005;
Narushima et al., 2006). Consistent with the presence of Ca2+-
assisted-Gq-receptor-driven eCB mobilization, our results re-
vealed that Oxo-M (1 mM) preincubation significantly enhanced
10 s DSE as compared to DSE examined under control condi-
tions (control DSE 84.82% ± 3.0% vs. Oxo-M DSE 60.72% ±
5.76%; t(18)=4.1, p<0.001) (Figures 4F and 4H). DSE undertative cell (J and K), and summary data of DSE after 2, 5 or 10 s of postsynaptic
llular BAPTA loading on DSE magnitude relative to control 10 s DSE. Control
p<0.01, ***p<0.001, and ****p<0.0001. Numbers of tested cells are indicated in
s. Calibration scale bars for sEPSCs (D) at lower magnification (10 pA, 100 ms)
s, 100 pA. Data presented as mean ±SEM. Also see Figure S1.
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Figure 4. mAChRs Modulate Glutamate Release and Enhance DSE
(A) One micromolar Oxo-M depresses fEPSP amplitude, which is blocked in the presence of atropine.
(B) Oxo-M-induced eEPSC depression is blocked by pirenzepine and 4-DAMP pretreatment.
(C) Oxo-M increases PPR, which is blocked by pirenzepine and 4-DAMP pretreatment.
(D) Representative traces of Oxo-M-induced eEPSC depression under vehicle, pirenzepine, and 4-DAMP conditions.
(E) Distribution of M1 receptor (red) and the dendritic marker MAP2 (green) in the CeAL at low magnification; higher magnification shows punctate M1 staining in
close apposition to MAP2 positive dendritic shafts (arrows in inset) (E1; scale bar 100 mm, E2; bar 5 mm, inset 7.5 mm).
(F) One micromolar Oxo-M enhances DSE induced by 10 s depolarization.
(G) PPR is increased by 10 s depolarization in both control and Oxo-M conditions.
(H) Representative traces of control and Oxo-M DSE.
(I) DSE in the presence of Oxo-M is attenuated by THL and in CB1
/ mice.
(J and K) Effects of pirenzepine and 4-DAMP on DSE in the presence of 1 mM Oxo-M; grey faded lines represent Oxo-M only DSE condition from (I) for visual
comparison purposes.
(L) Summary data of the effects of THL, CB1 deletion, pirenzepine, and 4-DAMP on 10 s DSE in the presence of Oxo-M. **p<0.01, ***p<0.001, and ****p<0.0001.
Scale bars are as follows: 10 ms, 100 pA. Data presented as mean ±SEM. Also see Figure S2.
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creases in PPR (p<0.05 and p<0.01, respectively, by paired
t test; Oxo-M DSE PPR is significantly greater than control
DSE PPR, p<0.05) (Figure 4G).
We next investigated the mechanisms of Oxo-M-mediated
enhancement of DSE in the CeAL. One-way ANOVA revealed
that 1 mM Oxo-M-mediated DSE enhancement was attenuated
in both Crn1/ CeAL cells (Oxo-M-WT 57.16% ± 2.56% vs.
Oxo-M-Crn1/ 87.03% ± 3.77%, p<0.0001) (Figures 4I and
4L) and CeAL cells pretreated with 10 mM THL for at least
60 min (Oxo-M 57.16% ± 2.56% vs. THL+ Oxo-M 86.08% ±
2.73%, p<0.0001) (Figures 4I and 4L). These results suggest
that the simultaneous activation of mAChRs and postsynaptic
depolarization results in the facilitation of 2-AG release at excit-
atory synapses within the CeAL. We next examined the musca-
rinic subtypes involved in the Oxo-M-mediated enhancement of
depolarization-induced 2-AG release. Application of the M1- or
the M3-preferring antagonists, 1 mM pirenzepine or 500 nM
4-DAMP, respectively, significantly reduced the 1 mM Oxo-
M-dependent DSE enhancement (Oxo-M 57.16% ± 2.56%
vs. Oxo-M+pirenzepine 73.92% ± 3.92%, p<0.01; Oxo-M
57.16% ± 2.56% vs. Oxo-M+4-DAMP 75.32% ± 4.75%,
p<0.01) (Figures 4J–4L). Collectively, these results suggest that
both M1 and M3 receptors play a role in the mAChR-mediated
enhancement of CeAL DSE. Interestingly, in Crn1/ mice 10 s
depolarization in the presence of Oxo-M elicited a small residual
DSE (baseline 100.0% ± 0.0% vs. 87.03% ± 3.77%, p<0.01 by
paired t test), suggesting possible CB1-independent residual
effects induced by depolarization in the presence of Oxo-M.
Acute mAChR-Driven eCB Signaling in the CeAL
To determine whether acute application of Oxo-M can induce
eCB release at CeAL glutamatergic synapses in the absence of
depolarization, we applied Oxo-M for 20 min and assessed
eCB release during this period using pharmacological and ge-
netic approaches (see Figure 5A for experimental design). Our
results revealed that Oxo-M application dose-dependently sup-
pressed eEPSC amplitude with maximal depression observed
with 1 mM Oxo-M (baseline 99.77% ± 0.54% vs. Oxo-M
34.61% ± 1.36%, p<0.0001 by paired t test) (Figures 5B–5D
and 5K). We next explored the contribution of CB1 receptor acti-
vation to Oxo-M-mediated synaptic depression. Maximal Oxo-
M-mediated depression was significantly attenuated in the pres-
ence of the CB1 receptor antagonist SR141716 following either
0.3 mM Oxo-M (Oxo-M 46.24% ± 4.25% vs. Oxo-M+SR141716
59.93% ± 2.81%; t(8)=2.69, p<0.05) or 1 mM Oxo-M application
(Oxo-M 34.61% ± 1.36% vs. Oxo-M+SR141716 53.11% ±
2.73%; t(17)=5.98, p<0.001) (see Figures 5C, 5D, and 5K).
We also examined the effects of SR141716 on Oxo-M-
induced elevation in PPR and found that SR141716 pretreatment
significantly attenuated the 1 mM Oxo-M-induced increase in
PPR (p<0.0001) (Figure 5E). Importantly, the residual Oxo-M
depression in SR141716-treated slices was associated with a
residual, significant increase in PPR (p<0.001) (Figure 5E), indi-
cating that the non-CB1 component of Oxo-M-induced depres-
sion is also presynaptic in nature. Given that Oxo-M-induced
synaptic depression is only partially CB1 dependent, we sought
to confirm these findings using Crn1/ mice. Oxo-M-inducedsynaptic depression was significantly attenuated in Crn1/
mice (WT Oxo-M 37.91% ± 2.83% vs. Crn1/ Oxo-M
55.94% ± 5.32%; t(12)=3.0, p<0.05) (Figure 5F). The maximal
1 mM Oxo-M-mediated increase in PPR was also significantly
attenuated in Crn1/ mice (p<0.001) (Figure 5G). Collectively,
these data indicate that Gq-receptor-driven eCB mobilization
can be initiated by mAChR activity in the CeAL, which, in turn,
contributes to Oxo-M-mediated synaptic depression of CeAL
glutamatergic transmission.
Acute mAChR Activation Drives Ca2+- and DAGL-
Independent eCB Release
In light of previous studies, the roles of intracellular Ca2+ and
DAGL in Gq-receptor-driven eCB release remain uncertain
(Edwards et al., 2006; Hashimotodani et al., 2005; Kim et al.,
2002; Tanimura et al., 2010; Zhang et al., 2011). Therefore, we
next examined the requirement for Ca2+ and DAGL activity in
acute mAChR-driven eCB mobilization in the CeAL. First, we
testedwhether Oxo-M-mediated eCB release requires increases
in intracellular Ca2+ concentrations [Ca2+]i. Postsynaptic loading
of the fast Ca2+ chelator BAPTA (20 mM) did not affect 1 mM
Oxo-M-mediated synaptic depression, and the maximal Oxo-
M-induced depression did not differ significantly from those
observed under control conditions (p>0.05) (Figures 5H and
5K). Similarly, THL pretreatment (10 mM;R60 min) did not inhibit
1 mMOxo-M-mediated depression of eEPSC amplitude (p>0.05)
(Figures 5I and 5K). Lastly, since a recent study suggested
phospholipase A2 (PLA2) may be required for 2-AG synaptic
signaling in the cerebellum (Wang et al., 2012), we tested the
involvement of PLA2 in Oxo-M-mediated synaptic depression
as an alternate mechanism by which mAChR activation could
release 2-AG. However, the PLA2 inhibitor AACOCF3 (10 mM)
did not significantly affect Oxo-M-mediated synaptic depression
(p>0.05) (Figures 5J and 5K). These data suggest that acute
mAChR-driven eCB release within the CeAL occurs indepen-
dently of increases in [Ca2+]i and does not require DAGL or
PLA2 activity.
Prolonged mAChR Activation Drives Ca2+- and DAGL-
Dependent eCB Release
The lack of calcium and THL sensitivity of acute Oxo-M-medi-
ated synaptic depression was somewhat surprising in light of
recent studies implicating Ca2+ and DAGLa in Gq-receptor-
driven eCB release (Castillo et al., 2012; Hashimotodani et al.,
2013; Katona and Freund, 2012). To exclude the possibility
that the non-CB1-dependent component of Oxo-M-induced
acute depression was potentially confounding our analysis, we
took an alternate approach aimed at selectively evaluating
CB1-dependent synaptic effects of Oxo-M. To do this, we pre-
treated slices with 1 mM Oxo-M for R60 min and subsequently
performed whole-cell patch clamp experiments where, after ob-
taining a stable baseline, we bath applied 5 mM SR141716 in the
continued presence of 1 mM Oxo-M (see Figure 6A for experi-
mental design). We reasoned that if prolonged mAChR activa-
tion induces tonic eCB release and activation of CB1 receptors
that subsequently depresses glutamatergic transmission, bath
application of a CB1 receptor antagonist should progressively
relieve this tonic eCB inhibition and cause an apparent synapticNeuron 81, 1111–1125, March 5, 2014 ª2014 Elsevier Inc. 1117
(legend on next page)
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Figure 6. Persistent mAChR Activity Drives
Ca2+- and DAGL-Dependent eCB Release
(A) Diagram of experimental design.
(B and C) Representative cells and group data
showing that in the continuous presence of
Oxo-M, SR141716 causes synaptic potentiation
relative to vehicle conditions.
(C) Coincubation of THL and Oxo-M prevents
SR141716-induced synaptic potentiation, as does
intracellular BAPTA loading.
(D) Summary data showing the effects of
SR141716 under vehicle, Oxo-M, Oxo-M+THL,
and Oxo-M+BAPTA pretreatment conditions.
(E) Representative traces of summary data in (D).
***p<0.001 and ****p<0.0001. Scale bars are as
follows: 10 ms, 100 pA. Data presented as
mean ±SEM.
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Endocannabinoid Signaling in the Central Amygdalapotentiation. Thus, this experimental design would allow us to
isolate eCB-CB1-mediated synaptic effects induced by pro-
longed mAChR activation. Consistent with this hypothesis,
SR141716 (5 mM) wash-on significantly increased eEPSC ampli-
tude in slices pretreated with 1 mM Oxo-M relative to control (no
Oxo-M) conditions (Figures 6B–6D). Maximal potentiation
induced by SR141716 in the presence of continuous Oxo-M
was 143.20% ± 6.59% compared to 113.30% ± 4.09% under
control conditions (p<0.001) (Figures 6B–6D). Interestingly, un-
like eCB release following brief Oxo-M application, continuous
mAChR activation appeared to promote eCB mobilizationFigure 5. Acute mAChR Activity Drives Ca2+- and DAGL-Independent eCB Release
(A) Diagram of experimental design.
(B–D) Oxo-M-induced eEPSC depression is partially blocked by SR141716 at 0.3 mM and 1 mM Oxo-M con
(E) One micromolar Oxo-M-induced increase in PPR is attenuated by SR141716; residual depression in the p
increase in PPR.
(F) One micromolar Oxo-M-induced eEPSC depression is attenuated in CB1
/ mice.
(G) The increase in PPR after Oxo-M application is attenuated in CB1
/ mice.
(H–K) Effects of BAPTA (H), THL (I), and the PLA2 inhibitor AACOCF3 (J), on 1 mM Oxo-M-induced eEPSC d
(K) Bar graph and representative traces of summary data depicting the effects of SR141716, THL, BAPTA, a
eEPSC depression. *p<0.05, ***p<0.001, and ****p<0.0001. Scale bars are as follows: 10ms, 100pA. Data p
Neuron 81, 1111–112through a THL- and a Ca2+-dependent
mechanism, as pretreatment with 10 mM
THL or 20 mM intracellular BAPTA com-
pletely abolished SR141716-induced
synaptic potentiation (p<0.0001 for each
condition) (Figures 6C–6E). Maximal
SR141716-induced enhancement after
10 mM THL pretreatment (vehicle
113.30% ± 4.09% vs. THL + Oxo-M
107.60% ± 7.54%, p=0.88) (Figures 6C
and 6D) or 20 mM BAPTA postsynaptic
loading (vehicle 113.30% ± 4.09% vs.
BAPTA+ Oxo-M 99.25% ± 6.10%,
p=0.34) (Figures 6C and 6D) was not
significantly different from SR141716-
induced synaptic potentiation under con-
trol (no Oxo-M) conditions. These data
suggest a possible temporal switch
from a BAPTA- and THL-insensitive to aBAPTA- and THL-sensitive mAChR-driven eCB release mecha-
nism following prolonged mAChR stimulation.
Acute mAChR Activation Drives Synaptic AEA Release
Several recent studies have indicated that Gq-coupled recep-
tors can mobilize AEA signaling (Cha´vez et al., 2010; Grueter
et al., 2010). As such, we sought to investigate whether the
Ca2+- and DAGL-independent acute Oxo-M-mediated synaptic
depression might be mediated via AEA, rather than 2-AG,
signaling. To examine this possibility, we determined the effects
of inhibiting AEA degradation with the fatty acid amide hydrolaseditions.
resence of SR141716 is associated with a residual
epression.
nd AACOCF3 on 1 mM Oxo-M-mediated maximal
resented as mean ±SEM.
5, March 5, 2014 ª2014 Elsevier Inc. 1119
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Endocannabinoid Signaling in the Central Amygdala(FAAH) inhibitor, PF-3845, on Oxo-M-mediated acute synaptic
depression (see Figure 7A for experimental design). PF-3845
(5 mM) pretreatment attenuated Oxo-M-mediated synaptic
depression at both 0.3 mM (p<0.01) and 1 mMOxo-M concentra-
tions (p<0.01) (Figures 7B–7D). We also tested the effects of the
monoacylglycerol lipase (MAGL) inhibitor, JZL-184 (2 mM), on
Oxo-M-induced synaptic depression to further rule out a role
for 2-AG in acuteOxo-M-mediated synaptic depression. Consis-
tent with the lack of BAPTA and THL sensitivity, prolongedMAGL
blockade did not significantly affect subsequent Oxo-M-medi-
ated acute synaptic depression at either 0.3 or 1 mMOxo-M con-
centration (p>0.05 for each) (Figures 7B–7D). Together, these
data indicate that inhibiting AEA, but not 2-AG, degradation
modifies acute Oxo-M-mediated synaptic depression; however,
the direction of effect was somewhat unexpected. Specifically, if
acute Oxo-M application causes release of AEA, blocking AEA
degradation would be expected to increase Oxo-M synaptic
depression rather than decrease it. The lack of enhancement
was not due to a floor effect, since both maximal and submaxi-
mal concentrations of Oxo-M showed reduced efficacy in the
presence of FAAH, but not MAGL, inhibition.
An alternate explanation for our results is that PF-3845, but not
JZL-184, occludes the effects of Oxo-M. If this were the case,
PF-3845 would be expected to cause synaptic depression
alone, which would then occlude subsequent AEA-mediated
synaptic depression initiated by acute Oxo-M application.
Consistent with this hypothesis, 5 mM PF-3845 wash-on pro-
duced a CB1-dependent synaptic depression of glutamatergic
transmission (PF-3845+vehicle 83.31% ± 5.34% vs. PF-
3845+SR141716 102.80%± 3.91%; t(14)=2.79, p<0.05) (Figures
7E and 7F). These data, combined with the lack of occlusion of
acute Oxo-M-mediated synaptic depression by the MAGL inhib-
itor JZL-184, strongly implicate AEA, rather than 2-AG, as the
eCB ligand subserving synaptic depression induced by acute
Oxo-M application. However, it is possible the lack of occlusion
by MAGL inhibition could be due to the fact that JZL-184 alone
did not produce synaptic depression. To exclude this possibility
and strengthen the support for an AEA-mediated process, we
tested the ability of JZL-184 to cause synaptic depression of
glutamatergic transmission. Consistent with our hypothesis,
JZL-184 produced aCB1-dependent synaptic depression of glu-
tamatergic signaling (JZL-184+vehicle 74.29%± 4.24% vs. JZL-
184+SR141716 96.38% ± 2.97%; t(9)=4.1, p< 0.01) (Figures 7G
and 7H). Taken together, these data provide converging
evidence that acute Oxo-M-mediated synaptic depression
causes synthesis/release of AEA that acts on CB1 receptors to
reduce glutamate release and that prolonged Oxo-M stimulationFigure 7. Acute mAChR Activity Drives Synaptic AEA Signaling
(A) Experimental design for (B)–(D).
(B–D) Oxo-M-induced acute synaptic depression (0.3 mMand 1 mM) is partially occ
course for 1 mM Oxo-M condition shown in (B).
(E and F) Effects of PF-3845 on synaptic depression under control or CB1 antag
(G and H) Effects of JZL-184 on synaptic depression under control or CB1 antag
(I) Diagrammatic representation of differences between acute versus prolonged m
‘‘burst’’ of AEA to reduce afferent glutamate release, while prolonged mAChR ac
(J) During prolonged mAChR activation, tonic 2-AG release continues and calcium
depolarization (i.e., DSE enhancement in the presence of continuous Oxo-M).
and **p<0.01. Scale bars are as follows: 10ms, 100pA. Data presented as meanof mAChRs enhances DSE and causes tonic CB1-mediated
synaptic depression via release of 2-AG through the canonical
calcium-DAGL-dependent pathway (Figures 7I and 7J).
Lack of Oxo-M-Mediated Acute or Tonic eCB Signaling
in Striatum
Thus far, our data indicate that acute Oxo-M activation of
mAChRs drives AEA release and subsequent depression of glu-
tamatergic signaling via CB1 activation. In contrast, prolonged
mAChR activity results in 2-AG-mediated tonic CB1 activation
and enhancement of DSE. Since our data suggest temporally
dissociated AEA and 2-AG release by the same stimulus, we
wanted to examine whether this was a generalizable phenome-
non. Therefore, we tested this phenomenon in the striatum given
the strong morphological, hodological, and cytoarchitectural
similarities between the striatum and the CeAL (McDonald,
1982). Acute application of Oxo-M (1 mM) caused robust presyn-
aptic depression in the striatum; however, this depression was
not affected by SR141716 pretreatment (p>0.05) (Figures S3A–
S3C). Similarly, SR141716 failed to produce synaptic potentia-
tion in the presence or absence of prolonged Oxo-M (1 mM)
pretreatment (Figure S3D). In contrast, prolonged Oxo-M
(1 mM) application was able to enhance DSE relative to control
conditions (p<0.01) (Figure S3E), and this enhancement was
blocked by SR141716 (p<0.0001). These data indicate that
Oxo-M (1 mM) is able to enhance DSE in the striatum but that
mAChRs do not trigger acute AEA or tonic 2-AG release to regu-
late glutamatergic transmission in this region. Thus, mAChR-
driven multimodal eCB release may not be a generalized feature
of central synapses.
DISCUSSION
eCB Signaling at CeAL Glutamatergic Synapses
Here we report the distribution and subcellular localization of
CB1 receptors and the 2-AG synthetic enzyme, DAGLa, in the
CeAL. In contrast to earlier studies, where CB1 receptor expres-
sion was below detection threshold in the CeAL (Katona et al.,
2001), here we utilized a high-affinity CB1 receptor antibody to
conclusively demonstrate the presence of CB1 receptor protein
in the CeAL (see Katona et al., 2006; Uchigashima et al., 2007).
High-resolution analyses showed CB1 receptors localized to
presynaptic terminals forming asymmetric synapses onto post-
synaptic dendrites and dendritic spines. DAGLa was observed
in the CeAL at both the mRNA and protein level, with ultrastruc-
tural studies demonstrating clear localization within postsyn-
aptic dendritic spine heads and dendritic shafts adjacent toluded by the FAAH inhibitor PF-3845, but not theMAGL inhibitor JZL-184; time
onist pretreatment conditions.
onist pretreatment conditions.
AChR activation with Oxo-M. Acute Oxo-M application induces a short-lived
tivation causes a tonic calcium- and DAGL-dependent 2-AG release.
-assisted mAChR-driven 2-AG release is induced by coincident postsynaptic
Ca+R-eCBR signifies calcium-assisted receptor driven eCB release; *p<0.05
±SEM. Also see Figure S3.
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tablished anatomical substrate for retrograde eCB signaling at
central synapses (Katona and Freund, 2012).
Consistent with our anatomical data, we found that activation
of CB1 receptors reliably reduced eEPSC amplitude, while
effects on GABAergic transmission were more variable (Katona
et al., 2001). Interestingly, the cannabinoid agonist, CP55940,
reduced eEPSC amplitude without a clear effect on PPR. In
contrast, 2-AG-ether and DSE both cause synaptic depression
associated with an increase in PPR. Although our data that
CP55940 affected the frequency, but not amplitude, of sEPSCs
suggest a presynaptic site of action, the lack of effect on PPR
was unexpected and inconsistent with the effects of DSE and
2-AG-ether. Although previous studies have shown presynaptic
inhibition of glutamate release in the CeAL by a decrease in the
number of release sites rather than release probability (Delaney
et al., 2007), the mechanistic discrepancy between different
CB1 ligands is more difficult to explain. One possibility could
be related to ligand-directed signaling at the CB1 receptor (Hud-
son et al., 2010), which would imply multiple presynaptic mech-
anisms downstream of CB1 receptor activation could result in
reduced glutamatergic transmission.
Multiple Modes of Postsynaptic eCB Mobilization by
CeAL Neurons
Consistent with our studies demonstrating eCB signaling ele-
ments at CeAL excitatory synapses and CB1 receptor-mediated
depression of glutamatergic signaling, we found that CeAL neu-
rons express prototypic 2-AG-mediated eCB signaling (i.e., DSE)
mediated via a calcium-dependent, THL-sensitive, and CB1-
dependent mechanism. These studies add to a recent demon-
stration of DSE in the CeAM (Kamprath et al., 2011) and tonic
eCB release at CeAM GABAergic synapses (Roberto et al.,
2010). We next examined themechanisms by which Gq-coupled
mAChRs initiate eCB signaling at CeAL glutamatergic synapses.
Our data indicate that acute application of Oxo-M causes a
robust presynaptic depression that is partially mediated via acti-
vation of CB1 receptors, consistent with findings in the periaque-
ductal grey (Lau and Vaughan, 2008). Mechanistically, this acute
CB1-dependent depression does not require elevations in
intracellular calcium, is THL-insensitive, and does not require
PLA2 activity. Moreover, inhibition of 2-AG degradation with
JZL-184 did not affect Oxo-M-mediated acute synaptic depres-
sion. Taken together, these data appear to exclude 2-AG as the
eCB ligand mediating the acute CB1-dependent synaptic
depression induced by short-term mAChR activation.
We next tested the hypothesis that another eCB ligand,
namely AEA, mediates eCB synaptic depression induced by
acute mAChR activation. We found that FAAH inhibition, which
on its own caused a CB1-dependent synaptic depression of glu-
tamatergic transmission, partially occluded acute Oxo-M-medi-
ated synaptic depression, implicating AEA in this process.
Huang and Woolley (2012), who showed that estrogen-induced
depression of GABAergic transmission in the hippocampus
was occluded by FAAH inhibition, but not MAGL inhibition,
reached similar conclusions in their system (Huang andWoolley,
2012). However, clear delineation of the biosynthetic pathway for
synaptic AEA synthesis and the development of pharmacolog-1122 Neuron 81, 1111–1125, March 5, 2014 ª2014 Elsevier Inc.ical tools to probe this system will be required to conclusively
assign AEA as the eCB ligand mediating acute Oxo-M-driven
synaptic depression.
In contrast to the putative AEA-mediated synaptic depression
induced by acute mAChR activation, prolonged activation of
mAChRs increases 2-AG-mediated signaling processes. First,
after prolonged Oxo-M incubation, DSE is enhanced in an
M1/3-dependent, THL-sensitive, and CB1-dependent manner,
which is consistent with findings in other brain regions (Kano
et al., 2009). Interestingly, our SR141716 wash-on studies re-
vealed strong synaptic potentiation by CB1 receptor blockade
in slices incubated with Oxo-M, but not vehicle. These data sug-
gest tonic eCB release can be induced by prolonged mAChR
activity. This synaptic potentiation required intracellular calcium
and was THL-sensitive, strongly suggesting that this Oxo-M-
induced tonic eCB signal is mediated by 2-AG synthesized by
the canonical calcium-DAGL-dependent pathway (Kano et al.,
2009). These findings are consistent with recent studies in
MAGL knockout mice, which suggest that 2-AG can act as a
tonic eCB retrogrademessenger (Pan et al., 2011). Overall, these
data indicate that CeAL neurons can mobilize multiple forms of
eCB signaling to modulate afferent glutamatergic transmission.
Functional Implications of Temporally Dissociated
Multimodal eCB Signaling
Previous studies have demonstrated that some cells can pro-
duce both AEA and 2-AG that act as retrograde eCBs signals
(Huang and Woolley, 2012; Kim and Alger, 2010; Lerner and
Kreitzer, 2012; Mathur et al., 2013; Puente et al., 2011). Similarly,
several studies have demonstrated that activation of Gq-
coupled receptors can induce 2-AG and also AEA release in
several brain regions (Cha´vez et al., 2010; Grueter et al., 2010;
Hashimotodani et al., 2013; Lerner and Kreitzer, 2012; Maccar-
rone et al., 2008). However, our data provide experimental evi-
dence that AEA and 2-AG can be differentially released in
response to activation of the same Gq-coupled receptor,
depending on the duration of Gq-receptor stimulation. Specif-
ically, acute mAChR activation causes short-lived AEA-medi-
ated synaptic depression, while prolonged mAChR stimulation
causes 2-AG-mediated tonic eCB depression of glutamatergic
transmission. Thus, in CeAL neurons, mAChR stimulation can
initiate multimodal eCB signaling depending on the duration of
Gq-receptor stimulation. Themechanistic basis for this temporal
‘‘switch’’ remains to be determined, but it is likely related to tem-
poral differences in the coupling of mAChRs to distinct signaling
pathways important for AEA and 2-AG synthesis (Mangoura
et al., 1995; McKenzie et al., 1992; Schmidt et al., 1995).
Recent studies have begun to highlight the dissociable roles of
AEA and 2-AG signaling on multiple levels. For example, in the
bed nucleus of the stria terminalis, AEA mediates long-term
synaptic depression, while 2-AG mediates short-term synaptic
depression in the form of DSE (Puente et al., 2011). In contrast,
in the striatum, different forms of associative neural activity can
elicit both AEA- and 2-AG-mediated long-term depression
(Lerner and Kreitzer, 2012). More recently, different inhibitory
synapses in the striatum have been shown to release AEA and
2-AG in a state-dependent manner (Mathur et al., 2013). Thus,
AEA and 2-AG are clearly not ‘‘redundant’’ signaling molecules
Neuron
Endocannabinoid Signaling in the Central Amygdalabut have distinct duration-, activity-, and synapse-dependent
effects. Here, we add to this eCB signaling diversity by demon-
strating temporally dissociated mobilization of AEA and 2-AG
signaling in response tomAChR activity. Continued investigation
of multimodal eCB signaling could provide insight into the activ-
ity-dependent mechanisms sculpting synaptic efficacy.
Here we show that eCB signaling suppresses afferent
glutamatergic transmission onto CeAL neurons, which could
represent an important synaptic mechanism regulating stress
response physiology and anxiety-like behaviors. Specifically, in-
hibition of excitatory drive to protein kinase C-d-expressing
GABAergic CeAL projection neuronswould disinhibit CeAMneu-
rons and increase fear and anxiety responses (Haubensak et al.,
2010). This model is consistent with well-known anxiogenic
effects of high doses of exogenous cannabinoids (Patel and
Hillard, 2006) and therefore could represent a synaptic correlate
of cannabinoid anxiogenesis. In contrast, inhibition of gluta-
matergic drive to somatostatin-expressing GABAergic neurons
could disinhibit CeAL projection neurons and, in turn, inhibit
CeAM activity, thereby reducing anxiety and fear responses,
which is the primary physiological function of eCB signaling
(Hill et al., 2009; Lutz, 2007; Riebe et al., 2012). Future studies
aimed at elucidating the afferent- and cell type-specific effects
of eCB signaling within the CeA microcircuitry will be critical to
advancing our understanding of the synaptic mechanisms by
which eCB signaling modulates stress-responses, anxiety, and
emotional learning.EXPERIMENTAL PROCEDURES
Animals
All studies were approved by the Vanderbilt University Institutional Animal
Care and Use Committee, as well as by the Committee of the Scientific Ethics
of Animal Research (22.1/4027/0033/2009). Furthermore, all studies were car-
ried out in accordance with the National Institute of Health Guide for the Care
and Use of Laboratory Animals, as well as the institutional guidelines of ethical
code and the Hungarian Act of Animal Care and Experimentation (1998. XXVIII.
Section 243/1998). See Supplemental Experimental Procedures for detailed
methods.
Anatomical Experiments
In situ hybridization, immunoperoxidase, and immunoelectron microscopy ex-
periments were conducted as previously described (Pe´terfi et al., 2012) and
detailed in the Supplemental Information. Briefly, we prepared antisense and
sense riboprobes against a 1,170-bp-long section (from position 1,967 to
3,136 in the open reading frame) of mouse DAGLa coding sequence using
the following primers: forward, 50-TCA TGG AGG GGC TCA ATA AG, and
reverse, 50-CTA GCG TGC CGA GAT GAC CA (Katona et al., 2006). The CB1
riboprobe was generated against a 738-bp-long region of mouse CB1 coding
sequence (from position 548 to 1,285 in the open reading frame; forward
primer, 50-CTA ATC AAA GAC TGA GGT TA, and reverse primer, 50- CAC
AGA GCC TCG GCA GAC GT). Free-floating immunoperoxidase staining
also followed the previously established protocol (Pe´terfi et al., 2012). For
EM analyses, after development of the immunostaining, the sections were
treated with 0.5% OsO4, dehydrated in an ascending series of ethanol and
acetonitrile solutions, and finally embedded into Durcupan ACM Fluka
(Sigma). During dehydration, sections were also treated with 1% uranyl ace-
tate in 70% ethanol for 20 min. After overnight incubation in Durcupan, the
sections were mounted onto glass slides and coverslips were sealed by
polymerization of Durcupan at 56C for 48 hr. From sections embedded in
Durcupan, areas of interest from the CeAL were re-embedded and resec-
tioned for electron microscopy.Electrophysiology
Whole-cell voltage clamp and field potential electrophysiological experiments
were carried out in 4- to 5-week-old male ICR mice as described previously
(Patel et al., 2009; Sumislawski et al., 2011). Briefly, mice were anesthetized
with isoflurane and transcardially perfused with ice-cold high-sucrose, low
Na+-containing ACSF. Following decapitation, the brain was removed and a
3mmcoronal block of the amygdala was cut using an ice-chilled, coronal brain
matrix. Thereafter, coronal slices (200–300 mm) were made using a Leica
VT1000S vibratome (Leica Microsystems, Bannockburn, IL) in 1C –4C
oxygenated (95% v/v O2, 5% v/v CO2) ACSF comprised of (in mM) the
following: 208 sucrose, 2.5 KCl, 1.6 NaH2PO4, 1 CaCl2,2H2O, 4 MgCl2,6H2O,
4 MgSO4,7H2O, 26 NaHCO3, 1 ascorbate, 3 Na-pyruvate, and 20 glucose.
Whole-cell voltage-clamp recordings were performed on CeAL neurons easily
identified visually by their medium-sized, spherical somata. Patch electrodes
were pulled on a Flaming/Brown microelectrode puller (Sutter Instruments)
and filled with solution containing (in mM) the following: 130 K+-gluconate,
4 NaCl, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, and 10 Na-phosphocreatine
(pH 7.25–7.35, adjusted with KOH). eEPSCs were recorded from CeAL neu-
rons via local microstimulation 100mm from the cell soma. Experimental de-
tails are described in the Supplemental Information.
Statistical Analysis
Statistical significance between the means of two groups was assessed using
two-tailed paired or unpaired t test unless variance differed significantly
(Bartlett’s test for equal variances), in which case nonparametric Mann-
Whitney (U) test was used. Statistical comparisons between two or more
groups were performed using one or two-way analysis of variance (ANOVA).
F and p values for ANOVA are provided above individual figures. Post hoc
analyses were conducted by Dunnett’s or Sidak’s test as indicated in the text.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.neuron.2014.01.012.
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